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Abstract 
Cost-effectiveness analysis is used to predict the optimal design of mass chemotherapy strategies in control- 
ling Ascaris lumbricoides infection. The question of who to treat, how many to treat, and how often to treat 
are addressed using a population dynamic model of hehninth transmission that assesses effectiveness in 
terms of disease reduction, combined with cost data from an actual control programme. Child-targeted treat- 
ment can be more cost-effective than population treatment in reducing the number of disease cases. The 
model also implies that, in the circumstances described here, enhancing coverage is a more cost-effective ap- 
proach than increasing frequency of treatment. 
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Introduction 
Chemotherapy is advocated as an affordable and effec- 
tive control measure for reducing intestinal nematode 
morbiditv (SAVIOLI et al.. 1992: WARREN et al.. 1992). 
However, the most cost-effective strategy of delivering 
chemotherapy to endemic communities remains uncer- 
tain. 
Theoretical analysis has shown that selective treatment 
(identifying and treating only those who are diagnosed as 
infected) can orovide substantial benefits both in terms 
of reducing the abundance of the parasite and the num- 
ber of treatments administered (ANDERSON & MAY, 
1982). However. the hiah cost of diaanosis and ooor 
com&tnce result in selective treatment being more ex- 
pensive and less effective than mass treatment in control- 
ling intestinal nematode infection (PRESCOTT, 1987; 
BUNDY, 1990). However, if mass treatment is the option 
of choice, there are still other design aspects which have 
to be considered. One issue is the target population: at 
whom should the drug be targeted?-the whole popula- 
tion, only high-risk groups such as school-age children, 
or a combination of .both? One also needs to consider 
how often the drug should be given and what proportion 
of the target population should be covered. It is not 
known, for instance, whether it is better to treat more 
people less frequently or less people more frequently. 
Ideally, one would require extensive field studies to in- 
vestigate these issues. However, such studies are expens- 
ive and time-consuming, as well as producing data re- 
stricted to a given endemic locality. 
A more immediate investigation into the most appro- 
oriate wavs of deliverine chemotheraov can be under- 
&en using theoretical &alysis. A population dynamic 
model of helminth transmission has been developed by 
MEDLEY et al. (1993) which allows estimation of the ef- 
fectiveness of different approaches to chemotherapy. 
This model has alreadv been used to investieate how 
often mass treatment should be administered &order to 
maximize cost-effectiveness (GUYATT et al., 1993). This 
study showed that less frequent treatments were most 
cost-effective in reducing the number of cases with heavy 
Ascaris lumbricoides infections, and that measuring effec- 
tiveness in terms of only the number of infections 
prevented produced misleading results. This study was 
confined to population mass treatment, and assumed a 
fured population coverage. 
The model has now been refined to include seoarate 
age groups, which allows investigation into age-targeted 
approaches to control (CHAN et al., in press). Although 
child-targeted treatment will never be more effective 
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than population treatment, it is less costly and may prove 
to be more cost-effective since this target group has the 
highest intensities of infection, and is therefore most 
likely to suffer disease and to be responsible for a larger 
proportion of the transmission stages (WARREN et al., 
1992). Indeed, the treatment of children only may also 
lead to the reduction of infection in untreated adults sim- 
ply from a reduction in the number of transmission 
stages; this has been observed in field studies (BUNDY et 
al., 1990). The age-structured population dynamic 
model has been shown to be a good fit to the observed 
data by CHAN et al. (in press), who also showed that 
population treatment followed by child-targeted treat- 
ment was more effective than child-targeted treatment 
alone, though the costs of these 2 programmes were not 
compared. 
In the first part of this paper, the cost-effectiveness of 
3 options for chemotherapeutic control of A. lumbricoides 
in a high and low transmission area are compared: popu- 
lation treatment, child-targeted treatment, and popula- 
tion treatment followed by child-targeted treatment. In 
this example, frequency of treatment and coverage are 
fixed. The interaction between coverage and frequency 
of treatment is complex and non-linear, and it is not im- 
mediately clear whether it is better to treat more people 
less frequently or less people more frequently. The sec- 
ond part of this paper will address this issue by compar- 
ing the cost-effectiveness of different combinations of 
frequency and coverage in delivering child-targeted treat- 
ment in a high transmission area. The predictions from 
the analyses will be used to provide some guidelines to 
the most cost-effective approaches to A. lumbricoides con- 
trol. 
Methods 
The model 
The model used to assess effectiveness has been de- 
scribed in detail by CHAN et al. (in press). Briefly, the 
host population is divided into 2 groups, children and 
adults, both of which harbour a parasite population of 
mature worms. A further parasite population is concep- 
tualized as a ‘pool’ of free-living infective stages in the 
environment. The host population can contaminate the 
environment by faeces containing eggs which develop 
into infective stages, and can become infected by contact 
with these infective stages. The 2 host groups differ in 
that the children both acquire infections and contaminate 
the environment at a higher rate than adults. The equili- 
brium worm population is set up using epidemiological 
parameter estimates of the life expectancy of the adult 
worm, the distribution of infection, and the rates of 
transmission. Left undisturbed, the parasite population 
will remain stable due to continual natural mortality of 
adult worms and infection by infective stages. Treatment 
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is simulated as instantaneous killing of adult worms in 
treated individuals. The efficacy of the drug is expressed 
as a proportion, an efficacy of 1.0 resulting in all worms 
in treated individuals being killed. The coverage and fre- 
quency of treatment can be varied and treatment given to 
the entire population or to one group alone. The changes 
in mean worm burden, prevalence of infection and pre- 
valence of morbidity in both host groups can be followed 
during and after several rounds of treatment. Morbidity 
is assumed to be associated with heavy infection by using 
a threshold worm burden at which morbidity occurs. 
Base case 
Treatment was assumed to be directed at A. lumbri- 
coides in high and low transmission areas. The epidemio- 
logical parameters used in the model are given in Table 
1. Population size was assumed to be 100 000, of whom 
Table 1. The epidemiological parameters for Ascaris 
lumbricoides transmission in a high and low transmis- 
sion area 
Transmission area 
Low High 
Pammete? Children Adults Children Adults 
W* 7 3 12 6 
: ;y4 074 OTso4 OY4 
RI l-25 3 1.5 
I-L (years) 1 1 1 1 
“The basic reproductive rate (&) and equilibrium worm burden 
(W*) were based on estimates by CROLL et al. (1982) for the 
high transmission area and CHAI et al. (1985) and BUNDY et al. 
(1987) for the low transmission area. The parameter k, an index 
of the degree of parasite aggregation, was taken from GUYATT et 
al. (1990) and the disease threshold (T) was based on analysis 
by GLJYATT & BUNDY (1991). The adult worms’ life expectancy 
(p) was based on studies reported by MULLER (1975). 
40 000 were children (C 15 years old) and 60 000 were 
adults (>15 years). Mass yearly treatment was assumed 
to be admimstered in years l-5; 90% of children were 
covered by the programme, and 50% of adults, reflecting 
typical levels of age-dependent compliance with a high 
rate of school attendance. The dru efficacy was assumed 
to be 0.9 for both children and ad UT ts. 
Scenarios 
Two scenarios extended from the base case were inves- 
tigated. The first was a comparison of 3 alternatives for a 
S-year mass annual treatment programme in high and 
low transmission areas. The 3 options were (i) population 
treatment in years l-5, (ii) child-targeted treatment in 
years l-5, and (iii) population treatment in year 1, and 
child-targeted treatment in years 2-5. 
The second scenario was a comparison of different fre- 
quencies of treatment and different coverages of a 5-year 
child-targeted treatment programme in a high trans- 
mission area. The different frequencies of treatment were 
(i) every 6 months, (ii) every year, and (iii) every 2 years, 
representing a total of 10, 5 and 3 treatment cycles re- 
spectively over the 5-year treatment period. Three levels 
of coverage were investigated; (i) 50%, (ii) 70% and (iii) 
90% of children. 
Cost analysis 
The cost data used in the analysis were based on actual 
expenditure of a control programme on the island of 
Montserrat (BUNDY et al., 1990). All costs are repre- 
sented in US$ at 1988 prices. Details of the cost data 
have already been given (GUYATT et al., 1993), and all 
unit costs, except transport costs, remain identical to 
those presented previously. The transport costs have 
been changed slightly for 2 reasons. Firstly, a 5% dis- 
count rate was used in annualizing the capital cost of the 
vehicle and, secondly, only the cost for the amount of 
time the vehicles were actually used has been attributed 
to the programme. In this analysis, one treatment cycle 
was assumed to require the vehicle for only 6 months; 
therefore the transport costs were half that of the pre- 
vious analysis for yearly and 2-yearly treatments. The 
transport costs also differed in child-targeted and popula- 
tion treatment because of the different sizes of the target 
population. The transport cost for child-targeted treat- 
ment was assumed to be half that for population treat- 
ment, as only one vehicle was required for child-targeted 
treatment, and 2 for population treatment. The cost of 
each delivery programme was assumed to be identical in 
both the high and low transmission areas. 
Effectiveness analysis 
In this study, effectiveness was confined to measures 
of the reduction in infection and disease prevalence as a 
result of the treatment programme. These 2 effectiveness 
measures were expressed as the number of infection cases 
prevented and the number of disease cases prevented, re- 
spectively. 
The total effectiveness was estimated as the sum of the 
effectiveness in children and adults, weighted by the pro- 
portions of children and adults in the po 
P 
ulation. The ef- 
fectiveness was assessed over a period o 10 years; for the 
duration of the 5 year treatment programme and for 5 
years following it. 
Cost-effectiveness analysis 
The use of discounting is essential to cost-effectiveness 
analysis, although the precise discount rate is controver- 
sial. In the present study, both the costs and effective- 
ness of each programme were discounted using a dis- 
count rate of 5% (DRUMMOND et al., 1987). Using 
alternative discount rates of 3% and 10% did not alter the 
qualitative results; the general conclusions remain un- 
changed (data not shown). 
The most effective option is that which maximizes the 
effectiveness measure (e.g. the number of disease cases 
prevented), while the most cost-effective option is that 
Table 2. A comparison of the cost-effectiveness of different treatment scenarios for ascariasis (A, child-targeted; B, 
population followed by child-targeted; and C, population) in low and high transmission areasa 
Low transmission area High transmission area 
A B C A B C 
cost (‘000, US$) 122 144 225 122 144 225 
Effectiveness (‘000) 
No. of disease cases prevented 
12 1;; 
50 
No. of infection cases prevented 249 E i: 1:; 
Cost-effectiveness ratio (US$) 
Cost per disease case prevented 2.94 3.34 4.53 l-78 1.92 2.45 
Cost per infection case prevented 1.12 1.04 0.90 l-84 1.70 1.38 
aAssuming treatment is given every year, when 90% of children and 50% of adults are treated. Cost and effectiveness 
have been rounded up to the nearest thousand, but the cost-effectiveness ratios were calculated from the original data. 
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which minimixes the cost-effectiveness ratio (e.g. the cost 
per disease case prevented). The incremental cost-effec- 
tiveness ratio indicates the extra costs required to achieve 
an extra gain in effectiveness by implementing amore ex- 
pensive but more effective option. 
Results 
ChiM-targeted and population treatment 
The cost and effectiveness of the 3 outions for aee- 
targeted treatment in the low and high traknission areas 
are given in Table 2. The cheapest option was child- 
targeted treatment, and the most expensive was popula- 
tion treatment. The cost of population treatment fol- 
lowed by child-targeted treatment lay between these. 
In both transmission areas, the most effective option 
was population treatment, since it prevented the highest 
number of disease and infection cases. Population treat- 
ment followed by child-targeted treatment prevented 
fewer cases than population treatment, but more cases 
than child-targeted treatment on its own. In terms of the 
number of infection cases prevented, the most effective 
and cost-effective option was population treatment. 
However, although population treatment prevented the 
highest number of disease cases, child-targeted treatment 
cost the least per disease case prevented, and was there- 
fore the most cost-effective option in terms of morbidity 
reduction. This highlights the problem of using the re- 
duction in infection cases as a measure of disease reduc- 
tion. 
The incremental cost-effectiveness ratio provides in- 
formation on the extra cost per extra unit gain in effec- 
tiveness, for employing the more effective, but more ex- 
pensive, option. Employing population followed by 
child-targeted treatment instead of child-targeted treat- 
ment alone cost US$ 2.90 per extra disease case 
prevented in the high transmission area, compared with 
US$ 12.20 in the low transmission area. Using popula- 
tion treatment alone instead of population followed by 
child-targeted treatment would have cost US$ 4.86 per 
extra disease case prevented in the high transmission area 
and US$l2.58 in the low transmission area. It is evident 
that it is less expensive per unit gain in effectiveness to 
move from child-targeted to population followed by 
child-targeted treatment han to choose population treat- 
ment alone instead of the combined approach. In both 
cases, the incremental cost-effectiveness ratios are higher 
Table 3. A corn arison of the cost-effectiveness of different 
combinations o F frequency of treatment and coverage for 
child-targeted treatment for ascariasis in a bigb transmission 
areaa 
FkyF of treatment 
Coverage 
Every Every 
6 months year 2 years 
cost (‘000, US$) 0.5 145 72 44 
0.7 194 97 58 
No. of disease 
cases prevented (‘000) 
No. of infection 
cases prevented (‘000) ;:; 45 
0.9 1:: 
t; 1: 
66 39 
Cost per disease 
case prevented (US$) ;:; 2.80 2.25 2.16 
2.77 1.95 1.78 
0.9 2.92 1.78 1.48 
Cost per infection 
case prevented (US$) ;:; 3.24 3.13 3.29 
2-59 2.41 2.53 
0.9 2.19 1.84 1.89 
“Cost and effectiveness have been rounded up to the nearest 
thousand, but the cost-effectiveness ratios were calculated from 
the original data. 
in the low transmission area, implying that implementa- 
tion of these more expensive options would be more fa- 
vourable in the high transmission area. 
Coverage and frequency of treatment 
The cost and effectiveness of the different combina- 
tions of frequency and coverage of child-targeted treat- 
ment in a high transmission area are given in Table 3. 
The most effective option, for both infection and disease 
case prevention, was to treat most people very frequently 
(i.e. 90% of children every 6 months). This was also, 
however, the most expensive option. The cheapest opi 
tion was to treat few oeonle less freauentlv (i.e. 50% of 
children every 2 years), but this was-also the- least effec- 
tive option. 
The most cost-effective option in terms of disease cases 
prevented was treatment every 2 years at a high coverage 
rate (90% of children). For infection case prevention, the 
most cost-effective option was treatment of 90% of child- 
ren every year. Here again, measuring effectiveness in 
terms of infection cases prevented can be misleading if 
the aim of control is to reduce disease. 
The incremental cost-effectiveness of increasing the 
frequency of treatment at a given coverage, or increasing 
the coverage at a given frequency of treatment, can also 
be important in deciding whether to invest in more fre- 
quent treatment or in enhancing the proportion of the 
population treated. 
Considering first the effect of increasing the frequency 
of treatment at any given coverage, the analysis demon- 
strated that increasing the frequency from every 2 years 
to every year cost an extra US$2.28-2.55 per extra dis- 
ease case prevented, depending on the coverage. Increas- 
ing the frequency of treatment from every year to every 6 
months required a much higher investment per extra dis- 
ease case prevented. It cost between US$ 3.72 and US$ 
8.23 per extra disease case prevented, the cost increasing 
with the coverage. This suggests that, whereas increasing 
the frequency of treatment to every year rather than 
every 2 years may be a reasonable option, increasing the 
frequency from every year to every 6 months may not be 
a good investment since the cost per extra disease case 
prevented is high, particularly at high coverage (Fig. 1). 
100 
Number of disease cases prevented (thousands) 
0 
0 50 100 150 200 250 
Cost (thousands US$) 
Fig. 1. The relationship between the cost and the number of 
disease cases prevented when increasing the frequency of 
child-targeted treatment given 3 levels of coverage: treatment 
every 2 years (O), yearly (0) and every 6 months (A). The 
dashed lines illustrate the extra cost and extra effectiveness of 
treating more fre uently, and the solid line represents the 
incremental cost-e fectiveness 9 ratio. 
For any given frequency of treatment, higher coverage 
resulted in more disease cases prevented, but at addi- 
tional cost. The cost per extra disease case prevented by 
treating more children varied with the frequency of treat- 
ment. The more frequent he treatments, the greater the 
investment required for every extra disease case 
prevented by treating a higher proportion of the child- 
ren. For instance, increasing the coverage from 50% to 
70% would cost US$ 2.67 per extra disease case 
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study predict that it is more cost-effective to extend the 
range of an existing cycle than to increase the number of 
cvcles. The main reasons for this are that, firstly, it is 
cheaper and, secondly the dynamics are such that the 
lower the infection levels achieved the slower the return 
to equilibrium levels due to reinfection. MEDLEY et al. 
(1993) showed that increasing the coverage of treatment 
was increasingly beneficial to the untreated proportion of 
the population, because of reduced infection rates. These 
results, however, are dependent on the level of trans- 
mission in the host community. Further research is con- 
tinuing to investigate the relationship between trans- 
mission, coverage and frequency of treatment. 
Number of disease cases prevented (thousands) 
100, I 
I 
50 100 150 200 250 
cost (thousands US$) 
Fig. 2. The relationship between the cost and the number of 
disease cases prevented when increasing the coverage of 
child-targeted treatment given different frequencies of treat- 
ment: 50% (II), 70% (0) and 90% (A) coverage. The dashed 
lines illustrate the extra cost and extra effectiveness of treating 
more children, and the solid line represents the incremental 
cost-effectiveness ratio. (These are the same data points as those 
in Fig. 1, but connected by different lines.) 
prevented if treatment were administered every 6 months, 
compared to US$ 1.17 with 2-yearly treatment cycles 
(Fig. 2). The lines are steeper in Fig. 2 than in Fig. 1, in- 
dicating more cost-effective increments. 
Discussion 
With the exception of drug efficacy, the coverage and 
frequency of treatment are often the only aspects of a de- 
livery programme that can be controlled. This analysis, 
therefore, addressed 2 central issues iu control design. 
Drug efficacy, which can be controlled through the 
choice of drug and dosage, will be the subject of a separ- 
ate analysis. 
This study investigated the issues of target group, 
coverage and frequency of treatment in the control of A. 
lumbricoides. Since the analysis was based on costs from 
au actual control programme, the results are clearly spe- 
cific to the programme described. The conclusions of the 
analysis may therefore not be applicable to all mass de- 
livery programmes. Nevertheless, one observation ap- 
plicable to hehuiuth control in general is that prevalence 
is a poor indicator of underlying disease patterns, yet it 
remains the most commonly used measure for assessing 
control (BUNDY et al., 1992). 
The analysis demonstrated that, of the 3 strategies of 
population and child-targeted treatment? child-targeted 
treatment alone was the most cost-effective option. The 
main reason for this was that the intensity of infection 
was highest in the child age classes, and therefore treat- 
ing children provided benefit to adults since the rate of 
transmission was greatly reduced. In this analysis, the 
unit cost of treating children was assumed to be identical 
to that for adults. In practice, the costs are likely to be 
much smaller for children, since they are more easily ac- 
cessible through schools (WORLD BANK, 1993). Includ- 
ing such a differential cost advantage would further fa- 
vour child-targeted treatment. 
The study investigated the optimal coverage and fre- 
quency of treatment by assessing the cost-effectiveness of 
child-targeted treatment in a high transmission area, 
given variation in how often and how many children 
were treated. Previous theoretical studies have investi- 
gated a control criterion for chemotherapy, which corre- 
sponds to the threshold coverage per rime period re- 
auired to eradicate infection or to control infection to a 
given level (ANDERSON & MAY, 1985; ANDERSON & 
MEDLEY. 1985). There has been no attemot. however. to 
dissect the interaction between coverage-and frequency 
of treatment, or to investigate the implications for cost- 
effectiveness. Since the programme was assumed to last 
for 5 years, it is obvious that the less frequent the treat- 
ments, the fewer treatments given. The results from this 
The most cost-effective option for child-targeted treat- 
ment was shown to be 2-vearlv treatment of 90% of the 
children. However, it is -possible that a 2-yearly treat- 
ment programme could be chosen, but only 70% cover- 
age achieved. In this situation, one may consider trying 
to increase coverage to 90%. This might involve extra 
cost to motivate the community (e.g. through health edu- 
cation) and the staff (e.g. through mcentives). In this in- 
stance; one would be‘injerested-m determining the maxi- 
mum amount of money that could be spent trying to 
achieve a 90% coverage, so that this would still be more 
cost-effective than leaving the coverage at 70%. This can 
be calculated by determining how much more the costs 
of the 90% coverage programme could be increased while - _ 
still maintaining a lower cost-effectiveness ratio than 
leavine coverage at 70%. The analvses uggested that, on 
top of-the extra treatment costs, it would-be possible to 
invest up to US$ 14 967 over the 5-year programme in 
increasing coverage from 70% to 90%, and this would 
still be the more cost-effective option. 
In the circumstances described here, enhancing cover- 
age is a more cost-effective approach than increasing fre- 
auencv. Further research wtll look at the sensitivnv of 
the results to variability in both the epidemiological-and 
economic frameworks. 
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